Fig. 1: Trial profile. | Nature Communications

Fig. 1: Trial profile.

From: Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

Fig. 1

The immunogenicity PPS analysis set included all participants who received two doses within the preset time window, had no major protocol violations, and had pre- and post-vaccination immunogenicity data available. 6 participants were excluded from immunogenicity PPS analysis set because of the second vaccination time beyond the time window, with 5 in LZ901 group and 1 in HZ/su group, see supplementary table 9. PPS, per-protocol set.

Back to article page